– Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis – Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020...
– Phase 1B Study Demonstrates the Potential of GS-6207 to Rapidly Reduce Viral Load After a Single Subcutaneous Injection – – Gilead Progresses Long-Acting Therapy Research Program to Help Address Real-World Challenges for People Living with HIV – March 11, 2020 03:09...
EXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -Idera Pharmaceuticals, Inc., Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year ended December 31, 2019. “In 2019, we made great progress with...
SAN DIEGO–(BUSINESS WIRE)– Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an interim clinical data update for cirmtuzumab, a ROR1-targeted...
Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology...
Email
Text